This is regardless of the fact that angiotensin-converting enzyme 2 (ACE2) (which is the SARS-CoV-2 receptor) is expressed more in the cholangiocytes (59.7%) compared to hepatocytes (2.6%) [62], which suggests that COVID-19-associated liver injury may be linked to cholangiocyte dysfunction [63]. Here, ACE2 is linked to COVID-19.